Provectus Admits Cash Running Low, Financing Coming Soon

Provectus Biopharmaceuticals (PVCT) issued a "CEO Letter" Tuesday regurgitating all the recent spin and ridiculously unrealistic talking points about the company's experimental (but already obsolete) melanoma therapy PV-10. You should read the letter for comic relief, but if you don't have the time, here's a few low-lights worth mentioning:

1. Provectus finally acknowledges the need to raise more money soon. "In total, we have adequate funds to operate without a further injection of capital through mid-2015," the company states. Uh oh. That's a problem because the planned phase III study of PV-10 won't start until later this year. Provectus executives have insisted previously that the company's cash on hand was sufficient to fund any future PV-10 clinical work. Tuesday, Provectus finally admits what every sentient investor knew all along: Dilution -- and lots of it -- is coming. 

2. A textbook example of how Provectus spins a greedy executive money grab into a shareholder win:

The Company's current cash position is sufficient to meet our obligations. In addition, management is returning $8.96 million to the Company as a result of the previously announced settlement of a shareholder derivative lawsuit (subject to a 2:1 credit to the executives, such that total actual repayment by the executives may be $1.12 million per executive) and further enhanced our strength by management's recent exercise of options.


Wow! Provectus executives must really care about their shareholders to return almost $9 million to the company. Not really, of course. A shareholder sued Provectus and its executives for granting themselves stock options and bonuses in violation of the company's executive compensation plan. A settlement of the lawsuit was reached in which Provectus executives were forced to repay the company. 

3. We have an electronic data room! We're going to sell the company! We promise! 

Pander. Pander. Pander. 

If you liked this article you might like

This Drug Company Loaned Its Now-Fired CEO $2.5M for Made-Up Travel 'Advances'

5 Breakout Stocks Under $10 Set to Soar

Biotech Stock Mailbag: Vanda, Navidea, Provectus

Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition